ReviewNeural plasticity2018
Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences.
Review in Neural plasticity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05711810 (Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- No association between acid suppressant use and risk of dementia: an updated meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Article
- Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2025Article
- Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole.Annals of medicine and surgery (2012) · 2025Review
- Gallic acid alleviates omeprazole-induced depressive behavior and memory impairment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Federated target trial emulation using distributed observational data for treatment effect estimation.NPJ digital medicine · 2025Article
- Federated Target Trial Emulation using Distributed Observational Data for Treatment Effect Estimation.medRxiv : the preprint server for health sciences · 2025Article
- Interplay between dietary nitrate metabolism and proton pump inhibitors: impact on nitric oxide pathways and health outcomes.Frontiers in nutrition · 2025Review
- Medication Exposure and Risk of Dementia and Alzheimer's Disease.International journal of molecular sciences · 2024Review
- The Effects of Omeprazole on the Neuron-like Spiking of the Electrical Potential of Proteinoid Microspheres.Molecules (Basel, Switzerland) · 2024Article
- Review
- Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks.Current Alzheimer research · 2024Review
- High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data.Nature communications · 2023Article
- Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease.Annals of medicine · 2023Article
- Article
- Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.Drugs & aging · 2023Article
- Is vitamin B12 deficiency a risk factor for gastroparesis in patients with type 2 diabetes?Diabetology & metabolic syndrome · 2023Article
- Modifiable contributing factors to COVID-19: A comprehensive review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023Review
- Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.